الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - carcinom, non-small cell lung - andra antineoplastiska medel, protein kinas-hämmare - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

astrazeneca ab - metformin hydroklorid, dapagliflozin propanediol monohydrat - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - xigduo är indicerat hos vuxna för behandling av typ 2-diabetes som ett komplement till diet och motion:• hos patienter otillräckligt kontrollerad på deras maximalt tolererad dos av metformin ensam • i kombination med andra läkemedel för behandling av diabetes hos patienter med otillräckligt kontrollerade med metformin och dessa läkemedel• hos patienter som redan behandlas med en kombination av dapagliflozin och metformin som separata tabletter. för att studera resultaten med avseende på kombinationen av behandlingar, effekter på glykemisk kontroll och kardiovaskulära händelser, och de populationer som studeras, se avsnitt 4. 4, 4. 5 och 5.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

astrazeneca ab - budesonid; formoterolfumaratdihydrat - inhalationsspray, suspension - 160 mikrogram/4,5 mikrogram/inhalation - budesonid 160 mikrog aktiv substans; formoterolfumaratdihydrat 4,5 mikrog aktiv substans

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - astma - läkemedel mot obstruktiv lungsjukdom, - fasenra anges som ett tillägg på underhållsbehandling hos vuxna patienter med svår eosinofil astma bristfälligt kontrollerad trots höga doser inhalerade kortikosteroider plus långverkande beta-agonister.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinom, non-small cell lung - antineoplastiska medel - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

astrazeneca ab - andexanet alfa - drog-relaterade biverkningar och biverkningar - alla andra terapeutiska produkter - för vuxna patienter som behandlas med en direkt faktor xa (fxa) - hämmare (apixaban eller rivaroxaban) när återföring av antikoagulation som behövs på grund av livshotande eller okontrollerad blödning.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

astrazeneca ab - metformin hydroklorid, saxagliptin, dapagliflozin - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - qtrilmet är indicerat hos vuxna i åldern 18 år och äldre med typ 2-diabetes mellitus:för att förbättra glykemisk kontroll när metformin med eller utan sulphonylurea (su) och antingen saxagliptin eller dapagliflozin inte ger tillräcklig glykemisk kontroll. när du redan behandlas med metformin och saxagliptin och dapagliflozin.

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

astrazeneca ab - budesonid; formoterolfumaratdihydrat - inhalationsspray, suspension - 80 mikrogram/2,25 mikrogram/puff - formoterolfumaratdihydrat 2,25 mikrog aktiv substans; budesonid 80 mikrog aktiv substans

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - pulmonell sjukdom, kronisk obstruktiv - läkemedel mot obstruktiv lungsjukdom, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.